Zydus Lifesciences Limited’s subsidiary, Zydus Pharmaceuticals (USA) Inc., has received tentative approval from the United States Food and Drug Administration (USFDA) for Gabapentin Tablets, the company said via an exchange filing.
The recommended daily dose is 300 mg or 600 mg (Gralise Tablets).
Gabapentin tablets are indicated for the management of Postherpetic Neuralgia (PHN).
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya.
UP-RERA Recovers ₹1410 Crore For Homebuyers, Resolves ₹5180 Crore In Claims Across 15,850 Cases
UP Sets ₹38 Lakh Crore Investment Goal: Invest UP To Convert 24,000 MoUs Into Production Units By December 2026
'He Doesn’t Trade In Hate': SP Counters Criticism Over Akhilesh’s Mosque Visit With Posters Promoting Religious Unity
'Wolf In Sheep's Clothing': UP Dy CM Keshav Maurya Slams Akhilesh At Sankalp Diwas; BJP Steps Up OBC Outreach for 2027
Gabapentin Tablets had annual sales of USD 90 mn in the United States (IQVIA MAT Dec. 2022).
The group now has 343 approvals and has so far filed over 440 ANDAs since the commencement of the filing process in FY 2003-04.
